Zymeworks Inc. Files 8-K Report
Ticker: ZYME · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1937653
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Zymeworks filed an 8-K, likely containing important updates for investors.
AI Summary
On November 21, 2024, Zymeworks Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or significant business events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Zymeworks Inc. is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational details that would indicate immediate risk.
Key Players & Entities
- Zymeworks Inc. (company) — Registrant
- November 21, 2024 (date) — Date of Report
- Delaware (location) — State of Incorporation
- 108 Patriot Drive, Suite A (address) — Principal Executive Offices
FAQ
What specific events are being disclosed under Regulation FD?
The provided excerpt does not specify the details of the Regulation FD disclosure.
Are there any new financial statements included in this filing?
The filing indicates that financial statements and exhibits are included, but the excerpt does not provide them.
What is the primary purpose of this 8-K filing?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering other events, financial statements, exhibits, and a Regulation FD disclosure.
When was Zymeworks Inc. incorporated?
Zymeworks Inc. was incorporated in Delaware.
What is the principal executive office address for Zymeworks Inc.?
The principal executive office is located at 108 Patriot Drive, Suite A, Middletown, Delaware 19709.
Filing Stats: 1,516 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2024-11-21 16:07:02
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
- $25 million — works has earned a milestone payment of $25 million based on the FDA approval in BTC. Zymew
- $500 million — works remains eligible to receive up to $500 million in regulatory milestone payments and $8
- $862.5 million — on in regulatory milestone payments and $862.5 million in commercial milestone payments, as we
Filing Documents
- d769907d8k.htm (8-K) — 41KB
- d769907dex991.htm (EX-99.1) — 43KB
- g769907g1121141122429.jpg (GRAPHIC) — 4KB
- 0001193125-24-263398.txt ( ) — 225KB
- zyme-20241121.xsd (EX-101.SCH) — 3KB
- zyme-20241121_lab.xml (EX-101.LAB) — 18KB
- zyme-20241121_pre.xml (EX-101.PRE) — 11KB
- d769907d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 21, 2024 104 Cover Page Interactive Data File (embedded as Inline XBRL document). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ZYMEWORKS INC. (Registrant) Date: November 21, 2024 By: /s/ Kenneth Galbraith Name: Title: Kenneth Galbraith Chair, President and Chief Executive Officer 4